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Diﬀerentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients
that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients,
however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases
are radioiodine avid. Cytotoxic chemotherapies for advanced or metastatic noniodine avid thyroid cancers show no prolonged
responses and in general have fallen out of favor. Novel targeted therapies have recently been discovered that have given rise to
clinical trials for thyroid cancer. Newer aberrations in molecular pathways and oncogenic mutations in thyroid cancer together
with the role of angiogenesis in tumor growth have been central to these discoveries. This paper will focus on the management and
treatment of metastatic diﬀerentiated thyroid cancers that do not take up radioactive iodine.
1.Introduction
Thyroid carcinoma is the most common endocrine malig-
nancy with a prevalence of 335,000 and incidence of 37,200
in the United States in 2009 [1]. Diﬀerentiated thyroid car-
cinoma, namely papillary and follicular thyroid carcinoma,
makes up about 94% of these cases. Despite the generally
good prognosis of thyroid carcinoma, about 5% of patients
will develop metastatic disease which fails to respond to
radioactive iodine, exhibiting a more aggressive behavior.
These patients will die of their disease [1–4].
85% of patients with diﬀerentiated thyroid carcinomas
are cured with surgery, radioactive iodine, and TSH sup-
pression. Of those that recur, the vast majority will recur
in the neck, and best treatment options are surgical with
potential further radioactive iodine. A small percentage of
patientswilldeveloporpresentwithmetastasesandaremore
diﬃcult to treat. When metastases have radioiodine avidity,
prognosis is better, and further radioactive iodine may be
used. However, when multiple doses of radioactive iodine
have been tried or the patient has nonradioactive iodine avid
disease, other options need to be considered. This paper will
aim to discuss the treatment options of those patients with
nonradioiodine avid, recurrent, or metastatic diﬀerentiated
thyroid cancer.
2.DiagnosisofRecurrent/Metastatic
DiseaseExtent
Screening ultrasound of the neck and tumor marker (thyro-
globulin)shouldbeperformedonallpatientswithdiﬀerenti-
ated thyroid cancer, per accepted guidelines [5]. The ﬁnding
of an elevated thyroglobulin or thyroglobulin antibody in
the face of a negative radioactive iodine scan is indicative
of non-radioiodine avid residual or recurrent disease. Both
ultrasound of the neck and thin spiral CT of the chest should
be performed for detection of disease. If symptoms occur
or the thyroglobulin is out of proportion to the amount of
disease seen, other imaging can be ordered as dictated by
the clinical scenario. Other imaging modalities include MRI
of the brain, spine, bone scan, and 18FDG-PET/CT scans.
Table 1 summarizes the imaging modalities used in thyroid
cancer surveillance.2 Journal of Thyroid Research
Table 1: Imaging modalities for RAI-refractory recurrent disease.
Imaging study Utility Pros Cons
Ultrasound neck Detection of neck disease Sensitive; ability to biopsy
Operator dependent; diﬃcult to
detect invasive disease and disease
in the posterior neck
CT Detection of local and metastatic
disease
Sensitive; less operator
dependent
Radiation exposure; risk of renal
injury with contrast; delays in
radioiodine administration
MRI Detection of local and metastatic
disease
Sensitive for CNS disease; no
radiation exposure
Diﬃcult to tolerate in some
patients; risk of nephrogenic
systemic ﬁbrosis (NSF) in patients
with renal failure; contraindicated
in patients with certain metal
devices or implants
FDG-PET scan
Detection of metastatic disease
and providing prognostic
information
Sensitive when used with CT Detects FDG-avid disease only
2.1. Role of Ultrasound. Ultrasonography (U/S) of the neck
(thyroidbedandcervicalneckcompartments),asopposedto
RAI scans, is recommended in the followup of these patients.
This shift in practice is due to the fact that many recurrent
tumors lose the ability to capture iodine, leading to false
negatives. As many as half of the patients with ﬁndings of
recurrence on U/S may have no uptake on radioiodine scan-
ning or may have an undetectable serum thyroglobulin [6].
Recurrence of papillary thyroid carcinoma is most com-
monly in the neck (thyroid bed and lymph nodes), and
hence, ultrasound is the mainstay of routine followup of
these patients. U/S can be used to accurately diagnose and
identify lesions in the neck as small as 3mm. Routine use
of U/S in the 3- to 12-month monitoring of patients with
extrathyroidal invasion or local-regional nodal metastases
[7, 8] is now recommended as part of consensus guidelines
[5]. Although U/S can aid in distinguishing benign lesions
from malignant lesions, FNA (U/S guided) is most helpful
to deﬁnitively prove recurrent cancer. Thyroglobulin can be
measured in the washout of the needle taken from neck
lymph nodes [9–11]. This is especially helpful in cases where
the FNA specimen is nondiagnostic.
2.2. CT and MRI. Other imaging techniques that can be
used in individual cases of thyroid cancer followup include
CT scan of the neck with IV contrast, CT scan of the
chest, and magnetic resonance imaging (MRI). MRI and
CT scan of the neck play important roles in the detection
of recurrent disease although the sensitivity of these is not
as well established as ultrasound for the detection of true
thyroid cancer recurrences in the neck. CT and MRI of the
neckarenotrecommendedforroutineuseinthedetectionof
recurrent disease but have the advantage of being much less
operator dependent. If good ultrasonography is not readily
available or deep posterior neck disease is suspected, CT and
MRI of the neck can be used for the detection of disease.
The most common place for papillary thyroid carcinoma
to metastasize outside the neck is the chest. CT scan of
the chest may show macro- and micronodular pulmonary
metastases that do not routinely take up iodine. This cross-
sectional imaging of the chest is used for long-term followup
when lung metastases are known or suspected based on
elevations in thyroglobulin.
CT and MRI scans of other less commonly found sites
of distant metastases include imaging of the brain, spine,
abdomen,andpelvisastheclinicalscenariodictatesbasedon
symptoms, clinical suspicion, or prior to initiation of various
therapies.
2.3. 18FDG PET-CT. Fluorodeoxyglucose positron-emission
tomography (FDG-PET or PET)/CT imaging is an increas-
ingly more useful tool in the detection of radioiodine-
negative, thyroglobulin-positive thyroid cancer [12–15].
Thyroid carcinomas with little to no iodine activity tend
to have higher glucose metabolism and positive FDG-PET
scans [12, 16, 17]. This tends to be representative of tumor
dediﬀerentiation. Patients with larger volumes of FDG-
avid disease or higher SUVs are less likely to respond
to radioiodine and have a higher mortality over a 3-year
followup compared with the patients with no FDG uptake
[18,19].Tumorsthattakeupradioactiveiodinearelesslikely
to yield positive FDG PET scans [20].
PET/CT scans can be used for detection of occult recur-
rences or metastases [16, 21, 22]o rt op r o v i d ei n f o r m a t i o n
about the biology of the metastatic disease and prognostic
information. The latter is not standard practice, but several
studies have now shown that FDG-PET correlates with the
overall survival [14, 15, 21]. This information may be helpful
to decide which patients warrant systemic treatment for
their metastatic disease if they are refractory/resistant to
radioactive iodine or have reached the maximum beneﬁt
from this treatment.
18FDG-PET has been approved for reimbursement for
the detection of occult thyroid cancer in patients who have
a thyroglobulin greater than 10ng/mL and have negative
radioiodine imaging. 18FDG-PET CTs are also used in thoseJournal of Thyroid Research 3
Table 2: Therapeutic modalities for RAI-refractory recurrent disease.
Indication Pros Cons
Surgery Surgically resectable local
recurrences; metastasectomy Potential for cure Potential signiﬁcant morbidity
External beam radiation
Adjuvant: neck
Therapeutic and palliative:
metastatic sites
Decrease in recurrence,
progression, and pain
May preclude future neck surgery;
dysphagia and xerostomia;
secondary malignancies
PEIT
Locally recurrent disease in
patients at high risk for
morbidity and mortality from
surgical resection
Potential for avoidance of
surgery
Local pain; injury to local
structures; unknown eﬀect on
survival and recurrence
Systemic chemotherapy
(including TKIs)
Unresectable, RAI-refractory,
metastatic disease
May slow progression of
disease; may alleviate disease
symptoms
Signiﬁcant adverse events;
unknown eﬀect on survival
PEIT: percutaneous ethanol injection therapy; TKI: tyrosine kinase inhibitors.
patients whose cancers are very poorly diﬀerentiated and
make no thyroglobulin.
The overall sensitivity, speciﬁcity, and accuracy of 18F-
FDG PET/CT in one series of 59 patients with radioiodine-
negative, thyroglobulin-positive, recurrent disease were
68.4%, 82.4%, and 73.8%, respectively [23]. Other studies
have shown a sensitivity of 70–95% and a speciﬁcity of 77–
100% [12, 13]. FDG-PET is not sensitive enough to detect
subcentimetermetastases,asitiscommoninmetastaticpap-
illary thyroid carcinoma and should be used in conjunction
with CT chest imaging.
TSH stimulates 18FDG uptake by diﬀerentiated thyroid
carcinoma [24], suggesting that PET scans may be more
sensitive after TSH stimulation with rhTSH or withdrawal
of thyroid hormone [24–26]. While rhTSH-stimulated PET-
CTidentiﬁedmoretotalFDG-avidlesionscomparedtonon-
stimulated FDG-PET CT in a large multicenter study, it
changed treatment planning only 6% of the time [27].
False positives, such as infections or granulomatous dis-
eases/sarcoid or postoperative changes due to inﬂammation,
amongst others, have been reported in thyroid cancer about
11–25% of the time suggesting that the malignant nature of
thediseaseshouldbeconﬁrmedpriortofurthertherapy[27–
30].
3 .T r eatm e n to fA d van c edo r
MetastaticThyroid Cancer
Most patients with diﬀerentiated thyroid cancers are ren-
dered free of disease after surgery, radioactive iodine, and
thyroid hormone suppression. Approximately 15–20% of
patients will recur locoregionally or have distant metastases.
Although it is the most eﬀective medical treatment for
diﬀerentiated thyroid carcinoma, only about 50–80% of pri-
mary tumors and their metastases take up radioactive iodine
[7, 31–34], rendering this therapy ineﬀective in most cases.
Thus, other treatment modalities such as surgery, external
beam radiation, percutaneous ethanol injection therapy
(PEIT), and systemic chemotherapy are indicated. Table 2
summarizes the indications for each of these therapies.
3.1. Surgery. Surgery in advanced thyroid carcinomas is
most commonly used for recurrent neck metastases and
metastasectomies in selected sites. Recurrences in the neck
are most commonly seen in the thyroid bed or regional
lymph nodes. Although most occur within the ﬁrst ﬁve years
after diagnosis, late recurrences do occur. In one study with
40-year followup, 35% of patients recurred. Two-thirds of
them were within the ﬁrst decade after initial therapy, and
two thirds were locoregional [35].
Surgery is considered ﬁrst-line therapy in patients with
gross nodal or recurrent neck disease. This can be followed
by further radioactive iodine (if the recurrent tumors took
up radioiodine prior to surgery) and thyroid hormone
suppression. One-third to one half of patients may be free of
disease in short-term followup [36] .I ft h eg r o s st u m o r sd o
not take up radioactive iodine from previous posttreatment
scans or preoperative radioiodine scans are negative, further
postoperative radioactive iodine will be of limited beneﬁt
and may increase the side eﬀects of further iodine. Adverse
events from further radioactive iodine include xerostomia,
nasolacrimal duct obstruction, and secondary malignancies
[37–42].
Surgery alone with complete ipsilateral compartmental
dissections of involved areas or modiﬁed neck dissections as
opposedto“berrypicking”orselectivelymphnoderesection
procedures or ethanol ablation may be of beneﬁt [43, 44].
It is not evident that recurrent locoregional disease in the
settingofdistantmetastaticdiseaseshouldberesected,unless
there is airway or an other vital structural compromise. If
the tumors invade the upper aerodigestive tract, a combined
treatment modality of surgery and 131I( i ft u m o r st a k eu p
radioactive iodine) and/or adjuvant external beam radio-
therapy is advised [45–48]. Due to potential morbidity from
surgical resection of recurrent disease, these patients should
be referred to centers with expertise in this area.
Surgery is also considered for isolated metastases, metas-
tases in bone (especially if long bones, spine, or weight
bearing), and brain (see Section 3.3 below).
3.2. External Beam Radiotherapy. External beam radiother-
apy (EBRT) has a very speciﬁc role in the treatment4 Journal of Thyroid Research
of papillary thyroid carcinoma. Although it is somewhat
controversial, retrospective studies have shown that it may
be an eﬀective adjuvant therapy to prevent local-regional
recurrence in patients 45 years of age and older with locally
invasive papillary carcinoma after surgery [49, 50]. Ten-
year local relapse-free rates (93% versus 78%) and disease-
speciﬁc survival rates (100% versus 95%) were higher in a
subgroup of patients with papillary histology and presumed
microscopic disease treated with EBRT [49]. Doses in the
range of 40–50 Gy may aid in local-regional control in
patients with papillary thyroid carcinoma who are over
45 years of age and have incomplete resection near the
aerodigestive tract and/or those with gross extrathyroidal
invasion with presumed microscopic residual disease. EBRT
is generally avoided in patients under 45 years of age both
because of their good prognosis and the potential late side
eﬀectsoftherapyincludingsecondarymalignancies.External
beam radiation may also preclude further surgery in the
future if the tumor recurs.
Acute complications of external beam radiotherapy in-
clude esophagitis and tracheitis. Long-term complications
include neck ﬁbrosis, xerostomia, dental decay, osteora-
dionecrosis, and the risk of tracheal stenosis [34]. Newer
techniques to deliver radiation with fewer adverse events are
being used in the treatment of cancer, including intensity-
modulated radiation therapy (IMRT). Limited data in
thyroid cancer with short-term followup suggests similar
outcomes and may reduce chronic morbidity relative to con-
ventional EBRT [51]. Many centers currently use IMRT as
the radiation treatment of choice for thyroid carcinomas
requiring EBRT [52].
3.3. Metastatic Sites Requiring Special Attention. Although
most patients with metastatic disease will need systemic
therapy, metastatic disease to certain sites deserves special
attention.
3.3.1. CNS Metastases. Brain metastases more often occur
in elderly individuals with more advanced disease and
have an overall poorer prognosis [53]. Surgical resection
signiﬁcantly improves median overall survival from four to
22 months in patients with 1 or more brain metastases [53].
Current guidelines recommend resection when one CNS
lesion is present [54]. Radioiodine therapy and/or exter-
nal beam radiotherapy (with steroids to minimize tumor
swelling) should be considered after surgical resection [55].
If CNS lesions are not surgically resectable or the morbidity
from surgery is unacceptable, whole brain radiotherapy for
numerous lesions or gamma knife radiosurgery to selected
lesions should be used in conjunction with radioiodine if
the tumor concentrates iodine [56]. If radioiodine is to be
used, prior radiotherapy and concomitant steroids should be
strongly considered to decrease tumor swelling [57].
3.3.2. Bone Metastases. Although bone lesions tend to con-
centrate radioiodine as well as lungs, there is complete
resolution in less than 10% of the time. Metastases that cause
pain or compression of spinal cord or other vital organs
necessitate treatment. Symptoms from painful bone lesions
or spinal-cord-compressing lesions may be relieved by
surgical treatment. External beam radiation therapy (EBRT)
or gamma knife radiosurgery has also been used successfully
to render bone lesions pain-free. Arterial embolization has
been used with successful reduction in pain and neurologic
symptoms and can be used in conjunction with external
beam radiation [58]. 131I treatment may follow surgical
resection of distant metastatic disease if the tumor takes up
radioactive iodine. A recent study found that patients with
solitary bony metastases treated with I131 and surgery had a
better prognosis than those who did not [59].
Intravenous bisphosphonates (pamidronate or zoledron-
ic acid) are prescribed for painful bony metastases with some
success as well. Orita et al., retrospectively, examined 50
patients with bony metastases from DTC and found that
those who had received monthly infusions of zoledronic
acidhadsigniﬁcantlyfewer-skeletalrelatedevents(deﬁnedas
fracture, spinal cord compression, and hypercalcemia) than
those who did not receive this drug [60]. Whether this treat-
ment slows progression of bone metastases is not known.
Themostcommonadverseeventassociatedwithintravenous
bisphosphonates is a transient ﬂu-like syndrome, usually
associated with the ﬁrst administration, with symptoms
dissipating and disappearing with subsequent infusions.
Osteonecrosis of the jaw is less common but serious adverse
event associated with intravenous bisphosphonates.
3.4. Systemic Therapy. Lack of RAI uptake by distant metas-
tases confers a poor prognosis. For example, patients with
no RAI uptake in the lungs have a 10-year survival rate of
25% compared with 76% in those whose lung metastases
have RAI uptake [61]. Pulmonary metastases that do not
take up radioactive iodine do not typically respond to that
radionuclide therapy, and these patients are at high risk of
death [62].
Most diagnostic scan-negative, thyroglobulin-positive
patients who have disease seen on other imaging modal-
ities are not rendered disease-free by repeat radioiodine
treatments, although tumor burden may decrease [63]. No
survival advantage nor decrease in morbidity has been seen
with repeat radioactive iodine therapies. Repeated doses of
radioactive iodine have been used in patients considered to
have radioactive noniodine-avid, thyroglobulin-positive dis-
ease with little clinical beneﬁt [64]. Although controversial, a
single dose of 100–150mCi of radioactive iodine therapy can
begiventoapatientwithelevatedthyroglobulinandnegative
diagnostic scan. A posttreatment scan should be done, and if
negative, further radioactive iodine should be avoided.
Repeated radioiodine therapy has adverse events includ-
ing xerostomia, nasolacrimal duct obstruction with epiph-
ora, and secondary malignancies [37–42]. Further radio-
active iodine therapy should generally be avoided in these
patients, and the use of systemic agents should be considered
[65].
Because metastatic diﬀerentiated thyroid cancer can be
stable and quiescent for many years, only patients with
progressive or symptomatic disease should be treated withJournal of Thyroid Research 5
other systemic treatments. Systemic therapy with targeted
agents or cytotoxic chemotherapy is the usual treatment
of choice for RAI-refractory, progressive distant metastatic
disease.
Clinical trials should consider ﬁrst-line therapy for those
patients who do not take up radioactive iodine. If a clinical
trial is not available or the patient is not suitable for one,
then oﬀ-label use of targeted therapies such as pazopanib,
sorafenib, sunitinib, or cytotoxic chemotherapy should be
considered [54].
3.4.1. Cytotoxic Chemotherapy. Traditional cytotoxic chemo-
therapies such as doxorubicin, taxol, and cisplatin are associ-
ated with a 25–37% partial response rate with rare complete
remission [66–69]. Due to toxic side eﬀects, short duration
of responses, and low response rates, systemic cytotoxic
chemotherapy is reserved for patients with rapidly progres-
sive metastatic disease that is not suitable or nonresponsive
to surgery, radioiodine, and external beam radiotherapy and
those who cannot enter into clinical trials or use targeted
agents (see below).
Systemic chemotherapy is used in certain cases of
widespread progressive disease that is radioiodine resistant
although available regimens have not been well studied and
are not very eﬀective to date. Doxorubicin is associated with
a response rate of up to 40% for progressive diﬀerentiated
cancers that do not respond to radioactive iodine [70, 71].
The recommended dosage is 60–75mg/m2 every 3 weeks.
Combination therapies are also used, but data are limited
because of the small number of patients in reported series.
Doxorubicin, epirubicin, taxol, and cisplatin have all been
used in various combinations; responses do not seem to
be any better than single agent with increased toxicities
[68, 69, 72]. Response rates vary from 25 to 37% with
mostly partial responses. Doxorubicin has also been used
as a radiation sensitizer with not much diﬀerent results
from radiation alone. Patients with advanced progressive
radioiodine nonresponsive disease should be considered for
participation in clinical trials.
3.4.2. Newer Targeted Therapies. Newer approaches to thy-
roid carcinoma therapy include inhibition of the various
metabolic pathways found to be altered in these cancerous
cells. Prior to the discussion of the available and tried
targeted therapies below, we brieﬂy summarize the known
aberrant pathways.
(1) Mutations and Promotion of Tumor Growth. Follicular
cell tumorigenesis pathways have been key to the devel-
opment of clinical trials testing novel therapies in the
treatment of thyroid cancer. Mutations in either BRAF, RAS
or RET/PTC rearrangements are present in most diﬀeren-
tiated thyroid cancers [73]. Chromosomal rearrangement
of the gene encoding the transmembrane tyrosine kinase
receptors ret and trk is one identiﬁed early step in the
development of these tumors. RET/PTC genetic alterations
have been found in 40% and 60% of papillary carcinomas in
adults and children, respectively, and are the most common
mutation found in the Chernobyl radiation-induced thyroid
carcinomas [74–76].
Mutations and constitutive activation of the MAP kinase
pathway have been of interest of late. BRAF (in papillary
thyroid cancer) and RAS genes in the MAP kinase pathway
normallycodeforgrowthandfunctioninnormaland tumor
cells. BRAF mutations have been identiﬁed in approximately
45% or more of clinically evident papillary carcinomas and
m a yb e h a v em o r ea g g r e s s i v e l y[ 77–79]. Activating mutations
of RAS are more common in follicular variant PTC and
follicular thyroid cancer [80] and may be a marker of more
aggressive disease [81].
Other discoveries include the dependence of tumors
on angiogenesis. Angiogenesis is important for tumor cell
growth, promotion, and development of metastases [82].
Vascular endothelial growth factor (VEGF), an important
proangiogenic factor, binds to VEGF receptors that in turn
can further activate MAP kinase signaling and promote
further tumor growth. VEGF receptors play a contributory
role in the development and progression of thyroid cancer
[73, 83]. VEGF expression is associated with higher risk of
recurrence and shorter disease-free survival [84, 85]. Like
in other tumors, epigenetic modiﬁcations of chromosomal
DNA and histones, including the promoter gene of the
sodium-iodine symporter, may also play an important role
in promotion of tumor growth.
(2) Therapeutic Options and Clinical Trials. Patients with
progressive or symptomatic metastatic thyroid cancer that is
deemed nonradioiodine responsive should be considered for
treatment on a clinical trial [5]. The recent identiﬁcation of
the molecular and cellular pathogenesis of both the devel-
opment and progression of cancer has led to development
ofnewermolecular-targetedtherapies.Oncogenicmutations
in the MAP kinase pathway (BRAF and RAS), as well as the
importanceofvascularendothelialgrowthfactorreceptorsin
thyroidcancer(mentionedabove),haveledtoseveralclinical
trials with small molecule inhibitors. These agents inhibit
multiple kinases and can aﬀect multiple signaling pathways.
Tyrosine kinase inhibitors (TKIs) are orally administered
and generally well tolerated. Immunomodulators, other
oncogene inhibitors, and modulators of growth or apoptosis
areallunderinvestigationaswell.Variousclinicaltrialsinthe
United States and Europe are recruiting diﬀerentiated thy-
roid cancer patients with radioiodine-negative progressive
disease. The following are among the ones that have raised
maximal interest and are summarized in Table 3.
(3) Commercially Available TKIs. (a) Sorafenib. Sorafenib
is an oral, small molecule tyrosine kinase inhibitor that
inhibits RET, BRAF, and VEGF receptors 2 and 3. It is
currently approved in the United States for advanced renal
cell carcinoma and unresectable hepatocellular carcinoma.
Two phase II trials have been performed in patients with
diﬀerentiated thyroid cancer that have both shown promise.
In the larger, National Cancer Institute sponsored study
with 58 patients with diﬀerentiated and anaplastic thyroid
cancer (46 diﬀerentiated thyroid cancer patients evaluable6 Journal of Thyroid Research
Table 3: Targeted therapies evaluated in clinical trials for thyroid cancer.
Drug VEGFR1 VEGFR2 VEGFR3 RET BRAF Other Response; PFS Citation
Axitinib X X X 31% PR; 18 mos (MTC
included) Cohen et al. [91, 99]
Motesanib X X X X 14% PR; 9 mos Sherman et al. [97]
Sorafenib X X X X 13–32% PR; PFS 10–21
mos
Kloos et al. [86],
Gupta-Abramson et al. [87],
Cabanillas et al. [88]
Sunitinib X X X X 28% CR + PR; TTP 13
mos Carr et al. [93]
Pazopanib X X X X 49% PR; PFS 12 mos Bible et al. [94]
Lenvatinib X X X X FGFR 50% PR; PFS 13 mos Sherman et al. [105]
Cabozantinib X X X c-MET 53% PR; PFS n/a Cabanillas et al. [101]
PR: partial response, SD: stable disease, TTP: time to progression, PFS: progression-free surivival, n/a: not available, and mos: months.
for response). The partial response rate was 13%, and
stable disease rate was 54% in patients with diﬀerentiated
thyroid cancer; however, 6 patients who were deemed
not assessable were excluded from this analysis [86]. A
second phase II study reported partial remission in 7 of
22 (32%) patients with diﬀerentiated thyroid cancer [87].
With early data showing sorafenib to have promise in
diﬀerentiated thyroid carcinoma (DTC) and sorafenib being
a commercially available drug, many clinicians began using
this drug in an oﬀ-label manner (not FDA approved for
thyroid cancer). We recently reviewed our experience with
oﬀ-label use of sorafenib in patients with DTC [88]. All
patients had progressive nonradioactive iodine-avid disease
to receive drug. Twenty percent of the patients developed
a partial response, and 60% of patients developed stable
disease achieving a clinical beneﬁt rate of 80%. Progression-
free survival was lengthened from four months predrug
to 19 months. There was no diﬀerence in response based
on BRAF mutational status in any of these studies thus
far. A phase III international randomized controlled trial
is underway currently evaluating sorafenib in progressive
nonradioiodine-responsive metastatic diﬀerentiated thyroid
cancer. This trial is randomized to placebo, and the primary
endpoint is progression-free survival.
(b) Sunitinib. Sunitinib is another oral small molecule
tyrosine kinase inhibitor that is FDA approved for the
treatment of metastatic renal cell carcinoma. This drug
inhibits RET, RET/PTC subtypes 1 and 3, and VEGFR [89].
Two patients with diﬀerentiated thyroid carcinoma treated
with daily sunitinib for four weeks and two weeks holiday
have had prolonged partial responses and decreases in SUV
on PET scan [90]. An ongoing open-label phase II study
showed a 13% partial response rate, and in another 68%
percent of diﬀerentiated thyroid carcinoma patients, disease
stabilization was seen [91]. A second phase II study has
reported partial remission or disease stabilization in two of
12 patients thus far [92]. Other case reports have described
prolonged partial responses [90]. The study by Carr et al. is
the largest published trial to date using sunitinib in patients
with metastatic PET-positive, RAI-refractory diﬀerentiated
thyroid cancer. 28% of patients with diﬀerentiated thyroid
cancer achieved a response (complete or partial response)
[93].
(c) Pazopanib. Pazopanib is a small molecule inhibitor
of all VEGFR subtypes and PDGFR. It is approved in
the United States for the treatment of advanced renal cell
carcinoma. Mayo Clinic recently reported on 37 rapidly
progressive DTC patients on a phase II single agent trial [94].
49% of patients had partial responses with a starting dose
of 800mg. Progression-free survival was 12 months. This
drug carries a black box warning due to severe and fatal
hepatotoxicity observed in a renal cell carcinoma patient.
Liver transaminase levels should be monitored closely with
this drug.
(d) Adverse Events Common to Sorafenib, Sunitinib, and
Pazopanib. Adverse events seen with these drugs are similar
to those described with the treatment of advanced renal
cell carcinoma and are summarized in Table 4. The most
common ones include diarrhea, hand-foot syndrome, rash,
hypertension, and fatigue. Skin changes have also been noted
including keratoacanthomas and squamous cell carcinomas
in about 5–11% of patients taking sorafenib. Due to the
promise shown by these agents in diﬀerentiated thyroid
carcinomaandtheavailabilityandtolerabilityofthesedrugs,
sorafenib,sunitinib,andpazopanibhavebeenaddedastreat-
ment options for patients with progressive nonradioactive
iodine-avid thyroid cancer who cannot be enrolled in a
clinical trial [5]. Due to signiﬁcant potential toxicity, only
clinicians versed in the management of the side eﬀects of
these therapies should use these drugs in a permissible oﬀ-
label manner.
(4) Clinical Trials with TKIs. (a) Motesanib. Motesanib is
an oral tyrosine kinase inhibitor that inhibits VEGFRs 1,
2, and 3 [95]. It is currently not commercially available. A
phase II trial was initiated based on responses in ﬁve patients
with diﬀerentiated thyroid cancer in a phase I trial [96].
Patients with progressive diﬀerentiated thyroid cancer based
on serial radiographic imaging in a six-month period were
enrolled in this international phase II trial. 93 patients were
enrolled, 14% had a partial response, and 35% of patients
developed disease stabilization for 24 weeks [97]. One-thirdJournal of Thyroid Research 7
Table 4: Adverse events associated with the commercially available TKIs used in thyroid cancer.
Adverse event Sorafenib (%) Sunitinib (%) Pazopanib (%)
All grade ≥grade 3 All grade ≥grade 3 All grade ≥grade 3
Hypertension 17 4 30 12 40 4
CHF or LVEF decline 1.7 NR 13 3 <1% NR
Proteinuria NR NR NR NR 9 <1
Hand-foot skin reaction 30 6 29 6 6 NR
Stomatitis NR NR 30 1 4 NR
Anorexia 16 <13 4 2 2 2 2
Weight loss 10 <11 2 <15 2 3 . 5
Diarrhea 43 2 61 9 52 3.5
AST elevation NR NR 56 2 53 7.5
ALT elevation NR NR 51 2.5 53 12
Fatigue 37 5 54 11 19 2
Hypothyroidism NR NR 14 2 7 NR
Arterial thromboembolism 2.9 NR NR NR 3 2
Hemorrhage/bleeding (all sites) 15 3 30 3 13 2
CHF: congestive heart failure; LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NR: notr e p o r t e d .
table adapted from [115].
of the patients were still on drug after 48 weeks. The median
progression-free survival was 40 weeks. Tumors with BRAF
mutations responded better than those without, despite the
lack of BRAF inhibition by motesanib, suggesting that these
BRAF-positive tumors may be more dependent on VEGF-
mediated angiogenesis. The most common adverse events
noted include fatigue, nausea, diarrhea, and hypertension.
This trial also noted the unanticipated side eﬀect of a
30% increase in levothyroxine requirement to maintain
the purposeful TSH suppression; two-thirds of the patients
developed a TSH outside of the range.
(b) Axitinib. Axitinib is an oral tyrosine kinase inhibitor
that blocks VEGFRs and has been studied in thyroid cancer.
It is not commercially available. A phase II, multicenter
study was initiated based on the experience of ﬁve thyroid
cancer patients in a phase I trial [98]. 31% of diﬀerentiated
thyroid carcinoma patients had a partial response [99].
Many of the patients had been previously treated with
various chemotherapeutic agents. Median progression-free
survival for all histologic types of thyroid cancer was 18
months. The most common side eﬀects seen in this trial
include hypertension, stomatitis, fatigue, and diarrhea. A
current trial is underway to evaluate axitinib’s eﬃcacy in
doxorubicin-refractory metastatic thyroid cancer patients.
(c) Other Therapeutic Agents. A small molecule inhibitor
of the epidermal growth factor receptor, geﬁtinib, has been
looked at in advanced thyroid cancer but had no complete
or partial responses [100]. With increased expression of c-
MET described in PTC, cabozantinib (XL184), an oral small
molecule inhibitor of various tyrosine kinases including C-
MET and VEGFR2, is being studied in diﬀerentiated thyroid
cancer[101–104].ResultspresentedattheAmericanThyroid
Association (ATA) were very encouraging, with a partial
response rate of 53% in a cohort of 15 DTC patients
[101]. A phase 2 trial with lenvatinib (E7080) in 58 patients
with radioactive iodine refractory DTC showed 50% partial
response and a progression-free survival of 13 months [105].
XL281, a small molecule inhibitor of BRAF kinases currently
in a phase I trial, preliminarily shows ﬁve patients with
papillary thyroid carcinomas with prolonged stable diseases.
Two of these patients had V600E BRAF mutation [106].
Vemurafenib (also known as PLX4032, RO5185426, and
RG7204), also a small molecule inhibitor of mutant BRAF
kinase, has shown promise in thyroid cancer [107]a n d
is currently being studied in patients with BRAF-mutated
thyroid cancer in a phase II trial. An open-label phase II
study in Kentucky examined the eﬃcacy of thalidomide
in progressive metastatic thyroid cancer of all histologies
[108]. An 18% partial response rate with 32% stable disease
as best response is described in the 28 evaluable patients
of all thyroid histologies. Lenalidomide, a similar drug to
thalidomide but less toxic, is being evaluated in a phase II
open-label study in DTC patients currently [109]. Thus far,
39% of the patients developed a partial response and 50% in
whom disease stabilized. Overall survival was shorter than in
most trials with a median of 11 months.
(d)AgentstoRestoreRadioactiveIodineUptake.Research-
ers have been searching for ways to restore loss of radioactive
iodine to nonavid tumors. 13 cis-retinoic acid partially
restored radioactive iodine uptake in poorly diﬀerentiated
follicularthyroidcancercells[110].Manyclinicaltrialsusing
retinoid receptors and other drugs have been focused on this
restoration of iodine avidity with little success. Bexarotene,
a synthetic agonist of the retinoid X receptor, was evaluated
in a phase II trial to attempt to restore radioiodine activity,
followed by treatment. After six weeks of therapy, eight of
11 patients had partial restoration of iodine avidity, but
there was not much tumor reduction [111]. Rosiglitazone, a
peroxisomalproliferators-activatedreceptor-gammaagonist,
was evaluated for restoration of radioiodine uptake [112].8 Journal of Thyroid Research
After eight weeks of treatment, although four patients had
iodine avidity, clinical response was lacking. Depsipeptide, a
histone deacetylase inhibitor, was evaluated in a phase II trial
of patients with nonradioiodine metastatic DTC [113]. Only
one patient out of 14 showed improvement in radioiodine
uptake, but signiﬁcant cardiac toxicities were seen, including
sudden death. The most encouraging of these studies was
presented at the American Thyroid Association (ATA) in
2011, evaluating single-agent MEK1/2 inhibitor, selumetinib
(AZD6244), in 17 patients who were RAI refractory. In
11 patients, RAI uptake was restored. Information on best
response was available in 7 patients, 6 of whom had a partial
response to RAI [114].
Other agents are under investigation in both phases I and
II studies, including agents that inhibit the PI3kinase/aKt
pathways, histone deacetylase inhibitors, and combinations
ofmethylationinhibitorswithhistonedeacetylaseinhibitors.
4. Summary
Diﬀerentiated thyroid carcinoma that is nonradioiodine avid
is diﬃcult to detect and treat. Clinically dictated selected
imaging including ultrasound of the neck, CT imaging of the
chest, MRIs of the spine and brain, bone scan, and 18FDG-
PET-CT have all been useful in the detection of disease.
Further radioactive iodine therapy in these patients tends to
increase adverse events with minimal clinical beneﬁt.
Recurrent neck disease is often treated with further
surgery. In addition, patients may beneﬁt from resection of
speciﬁc symptomatic metastatic sites. Selected patients may
beneﬁt from external beam radiotherapy, radiofrequency
ablation, or chemoembolization of other metastatic sites as
well.
Patients with stable metastatic disease may be observed
with thyroid hormone suppression therapy only. More
advanced, progressive neck disease and progressive, distant
metastatic disease require systemic treatment. Cytotoxic
chemotherapy has limited response rates and signiﬁcant
toxicity and is therefore reserved for symptomatic pro-
gressive disease in a patient that cannot get on a clinical
trial or tolerate antiangiogenic therapy. The advancement in
understanding the molecular aberrations in thyroid cancer
has led to an explosion of promising recent clinical trials.
Targeted agents against the VEGF receptor and the MAP
kinase pathway are amongst the most promising thus far.
These agents have shown some of the most impressive
responses and have fairly tolerable adverse eﬀects.
Given our current knowledge and trial results, it remains
diﬃcult to choose the optimal therapy for selected patients.
Many of the trials had varying entry criteria, many of
which did not require progression. No trial thus far has
overall survival as the primary endpoint, prolongation of
this being the ultimate goal of patients. In addition, most
patients eventually progress through these agents suggesting
development of other pathways of resistance. Future trials
will likely necessitate combination of therapy with minimal
increased toxicity. Future trials may include agents that
inhibit the PI3 kinase pathway in addition to the MAP kinase
pathway or combination of cytotoxic chemotherapy with
targeted agents. The main goal of all these trials should be
to prolong life with minimal decrease in quality of life.
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